Drug Profile

MR 001

Alternative Names: MR-001

Latest Information Update: 14 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vacino Biotech
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

06 Oct 2025 Shenzhen Majory Biotechnology plans phase I/II in Triple-negative breast cancer (Late-staged disease, Metastatic disease, Second line therapy or greater and Recurrent) in China (IV) in October 2025 (NCT07208149)
19 Dec 2023 Discontinued for Breast cancer in China (Parenteral) (Vacino Biotech pipeline, December 2023)
19 Dec 2023 Discontinued for Lung cancer in China (Parenteral) (Vacino Biotech pipeline, December 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com